EUVIMEDEUVIMED entdecken
Open Access

Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide

Mohamed El Fakiri, Anusha R Regupathy, Lisa Uhlmann, Nawal Ayada, Nicolas M Geis, Lisa-Charlotte Domogalla, Johanna Lahdenranta, Ben Blakeman, Francesca Wood, Philipp T Meyer, Philip Huxley, Matthias Eder und 2 weitere

Theranostics · 2024

DOI: 10.7150/thno.96641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Mohamed El Fakiri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, …. Hauptthemen laut MEDLINE: Receptor, EphA2. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, EphA2AnimalsHumansMiceCell Line, TumorTissue DistributionPeptides, CyclicRadiopharmaceuticalsMaleMice, NudeXenograft Model Antitumor AssaysMice, Inbred BALB CLutetiumIndium RadioisotopesRadioisotopesFemaleGallium RadioisotopesProstatic Neoplasms

Stichwörter der Autor:innen

PET imagingbicyclic peptidecancer imaging.radionuclide therapytheranostics

Substanzen

Receptor, EphA2EPHA2 protein, humanPeptides, CyclicRadiopharmaceuticalsLutetiumIndium RadioisotopesRadioisotopesIndium-111Lutetium-177Gallium Radioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.
  • Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany and German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelbe…
  • Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany.
  • BicycleTx Limited, Portway Building, Granta Park, Cambridge CB21 6GS, United Kingdom.
  • Bicycle Therapeutics, 35 Cambridgepark Drive, Cambridge, MA, 02140, United States.

Zitieren

APA

El Fakiri, M., Regupathy, A. R., Uhlmann, L., Ayada, N., Geis, N. M., Domogalla, L. C., Lahdenranta, J., Blakeman, B., Wood, F., Meyer, P. T., Huxley, P., Eder, M., Mudd, G. E., & Eder, A. C. (2024). Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide. Theranostics. https://doi.org/10.7150/thno.96641

Vancouver

El Fakiri M, Regupathy AR, Uhlmann L, Ayada N, Geis NM, Domogalla LC, et al. Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide. Theranostics. 2024. doi:10.7150/thno.96641

BibTeX
@article{ElFakiri2024,
  author = {El Fakiri, Mohamed and Regupathy, Anusha R and Uhlmann, Lisa and Ayada, Nawal and Geis, Nicolas M and Domogalla, Lisa-Charlotte and Lahdenranta, Johanna and Blakeman, Ben and Wood, Francesca and Meyer, Philipp T and Huxley, Philip and Eder, Matthias and Mudd, Gemma E and Eder, Ann-Christin},
  title = {Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide},
  journal = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.96641}
}
Kostenlos starten →